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pathogenesisandrelationship to theassociatedmalignantcon-
dition are not well understood. Theories include tumor anti-
gens cross-reacting with antigens of the skin BMZ, a cellular
immune response with cytotoxic effects, tumor growth fac-
tors inducinghyperkeratosis (transforminggrowthfactorα,epi-
dermal growth factor, or insulin-like growth factor 1), or zinc
and vitamin A deficiency from tumor expansion.5,6
Theeruption is generally symmetric andnonpruritic,with
violaceous to pink patches and plaques with hyperkeratosis
of acral sites.3-5 The extremities and trunk can be involved.3-6
The palms and solesmayhavehyperkeratosis and fissures, as
in keratoderma.5 Nail changes are frequently seen, including
onycholysis and subungual debris.4 Edema of the distal ex-
tremities and vesicular formation is infrequently seen.3,5,7
The cutaneous manifestations present, on average, 11
monthsprior to thediscoveryofcancer,but in20%of thecases,
the malignant neoplasm is diagnosed at the time of the skin
eruption.5,6 Squamous cell carcinoma is the most commonly
associatedmalignant condition.6Other cancers includepoorly
differentiated carcinoma, adenocarcinoma, small cell carci-
noma, lymphoma, and cholangiocarcinoma. The majority of
associated malignant neoplasms occur above the diaphragm
and involve the upper one-third of the aerodigestive tract.
Bazex syndrome may resemble more common diseases
such as psoriasis. Therefore, a biopsy is generally helpful,
though the findings are typically nonspecific. Common re-
ported findings includehyperkeratosis, acanthosis, parakera-
tosis,dyskeratotickeratinocytes,andperivascular infiltrates.4,5
Immunofluorescence has been performed in a minority of
cases, and its results are generally nonspecific.5 Our patient’s
clinical findings were concerning for a blistering disease, but
neither hematoxylin-eosin nor direct immunofluorescence
evaluation showed evidence of bullous pemphigoid or para-
neoplastic pemphigus.
Symptomatic improvementcanbeachievedbytreating the
underlyingmalignant condition; returnof skin lesions can sig-
nal tumor recurrence.5 While skin-directed therapymight be
helpful to control symptoms, the responses are variable and
suboptimal.
Insummary,wepresenthereinacaseofacrokeratosispara-
neoplasticawith rapidonset of cutaneous findings and thede-
velopmentofmanyvesicles andbullae.Furthermore,wedem-
onstrate thediagnostic roleofbiopsyand immunofluorescence
testing in this patient.
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Erythrodermic Epidermolysis Bullosa Acquisita
Epidermolysis bullosa acquisita (EBA) is a rare acquired sub-
epidermal blistering autoimmunedisease of the skin andmu-
cosae associatedwithautoantibodiesdirectedagainst typeVII
collagen, themajor component of the anchoring fibrils of the
dermal-epidermal junction.1,2Various clinical presentationsof
EBAhavebeendescribed, includinganoninflammatorymecha-
nobullous form, an inflammatory bullous pemphigoid (BP)-
like form, and a mucous-membrane pemphigoid-like form.
These formsmay show clinical overlap, and their courses are
often unpredictable.1-3
Report of aCase |A60-year-oldmanwasadmitted forevaluation
ofa3-weekhistoryofwidespreadpruriticcutaneouslesions.The
patient had taken no drugs, and hismedical historywas unre-
Figure 2. Histologic Specimen From theWrist Showing Acrokeratosis
Paraneoplastica
At lowmagnification (×40), there is an acanthotic andmildly spongiotic
epidermis with minimal interface, eosinophils in the dermis, and overlying
parakeratosis (hematoxylin-eosin).
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markable.Onexamination,almosthisentiretrunk,buttocks,and
thighswere erythematous and infiltratedwithpapular andur-
ticarial lesions (Figure1). Islandsofnormal-appearingskinwere
observed.Onhis solesandpalms, isolated lesionswitha target-
likeappearancewerenoted.Theheadaswellastheoralandgeni-
talmucousmembraneswerespared.Duringhospitaladmission,
thepatientdevelopedisolatedvesiclesandserousblistersonery-
thematous skin on hiswrist and ankle.
Light microscopy studies of a skin biopsy specimen ob-
tained frompatient’s back showed a diffuse spongiosiswith a
mixed perivascular inflammatory infiltrate consisting of eo-
sinophils and neutrophils in the upper dermis (Figure 2). Di-
rect immunofluorescence microscopy studies disclosed lin-
ear deposits of IgG and C3 along the epidermal basement
membrane zone. By indirect immunofluorescence micros-
copyusingsodiumchloride–separatednormalhumanskin, cir-
culating IgGautoantibodiesbinding thedermal sideof the split
were detected.
Immunoblotting analysis using human dermal extracts
showeda reactivitywith a 290-kDaprotein showing the same
electrophoretic migration to the protein band recognized by
the control monoclonal antibody directed against type VII
collagen.
Based on the clinical features and immunopathological
findings, thediagnosisofEBAwasmade.1Thepatientwasgiven
oral prednisolone, 0.75mg/kg of bodyweight,which resulted
in rapid clearance of the lesions within 2 weeks. Corticoste-
roid doses were subsequently slowly tapered. At a dose of 10
mg/d, the patient experienced a relapse and began treatment
with methotrexate, 15 mg subcutaneously once weekly. The
prednisolone dose was then tapered to 2.5 mg/d, and the pa-
tient remained asymptomatic at 6-month follow-up.
Discussion | The clinical features of EBA are protean. The clas-
sic presentation is that of a noninflammatory mechanobul-
lous disease characterized by the development of acral blis-
ters that heal with atrophic scarr ing, mi l ia , and
hyperpigmentation or hypopigmentation. They are localized
to trauma-prone surfaces such as elbows, knees, hands, and
feet.1-3 Acral involvement may be mutilating. Scalp involve-
ment occurs in up to 20% of patients.1-3 The inflammatory
BP-like presentation is associated with widespread vesicles
and bullae involving intertriginous and flexural areas that
heal without atrophic scarring.1-3 Epidermolysis bullosa
acquisita may also present as mucous membrane pemphigoid
or as Brunsting-Perry pemphigoid phenotype.3 The potential
causes of erythroderma include psoriasis, atopic dermatitis,
drug reactions, and cutaneous T-cell lymphoma. With the
exception of pemphigus foliaceus, the other autoimmune bul-
lous diseases of the skin have been only anecdotally impli-
cated as cause of erythroderma. Specifically, single cases of
erythrodermic BP have been described.4,5 Epidermolysis bul-
losa acquisita is potentially associated with a number of sys-
temic diseases, including inflammatory bowel diseases,1,3 but
our patient showed no evidence of any of these.
Figure 1. Clinical Appearance of Erythrodermic Epidermolysis Bullosa
Acquisita
The patient has generalized erythematous confluent papular and urticarial
lesions on the trunk.
Figure 2. LightMicroscopy Study of a Skin Biopsy Specimen From
Patient’s Back
Specimen shows epidermal spongiosis with a mixed perivascular inflammatory
infiltrate composed of eosinophils and neutrophils in the upper dermis
(hematoxylin-eosin, original magnification ×40).
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Our casewas striking because the patient initially showed
features suggestive of either a severedrug reactionor a paravi-
ral eruption, but immunopathological studieswere diagnostic
forEBA.Ourobservationprovides a further exampleabout the
polymorphousandmisleadingpresentationsofEBA.Hence,EBA
should be considered as a rare cause of erythroderma.
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CORRECTION
MissingMiddle Initial inAuthor’sName: In theObservation letterentitled “Acute
OnsetofAcrokeratosisParaneoplastica (BazexSyndrome)”published in theMarch
11, 2015, online first issue of JAMADermatology (doi:10.1001/jamadermatol.2014
.5622), an author’s middle initial was not included in the byline. The author’s full
name is Amara S. Hussain. This article was corrected online.
Incorrect Figure: In the article titled “Intralesional Rituximab in the Treatment of
Refractory Oral Pemphigus Vulgaris,” published online December 23, 2014, in
JAMA Dermatology (doi:10.1001/jamadermatol.2014.3674), incorrect images
appeared in a figure. As a result of human error, Figure 2A was inadvertently
published upside down. Both images in Figure 2 are now replaced. In addition,
the figure caption should have read as follows: “Clinical photographs of the right
buccal mucosa in patient 3 show progress of oral PVwith rituximab treatment. A,
Pretreatment photograph showing persistent oral erosions. B, Posttreatment
photograph at week 16 showing complete healing.” This article was corrected
online.
Error in Byline: In the article “Narrowband UV-B Phototherapy for Steroid-
Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease,” published online
March 25, 2015 (doi:10.1001/jamadermatol.2015.0175), the name of the second
author listed in the byline has been corrected from Rachel Holtzman, BS, to Ra-
chel McAndrew, BS. The author contributions have been corrected to reflect this
changeandnowreadas follows: “AuthorContributions:MrSorensonandDrLevin
had full access to all of the data in the study and take responsibility for the integ-
rity of the data and the accuracy of the data analysis. Study concept and design:
Sorenson, Logan,Koo, Levin.Acquisition, analysis, or interpretationof data:All au-
thors. Drafting of the manuscript: Sorenson, McAndrew, Patel, Logan, Koo. Criti-
cal revision of themanuscript for important intellectual content:All authors. Study
supervision: Sorenson, Logan, Koo, Levin.”
Error in Text: In the Research Letter by Chen et al titled “γ-SecretaseMutation in
anAfricanAmericanFamilyWithHidradenitis Suppurativa,” publishedonlineFeb-
ruary 18, 2015, in JAMADermatology (doi:10.1001/jamadermatol.2014.5306), an
incorrect number of families was given in the second sentence of the first para-
graph. The sentence should read as follows: “Heterozygous mutations in the
γ-secretase genes have been identified in the pathogenesis of autosomal domi-
nant forms of HS in 2 British, 11 Chinese, 1 Japanese, and 3 French families.1” This
article was corrected online.
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